Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-transporters

Biochemical Pharmacology

Volumn 80, Issue 4, 2010, Pages 471-479

  Schumacher, Marco ^a   Hautzinger, Anja ^a   Rossmann, Annette ^a   Holzhauser, Susanne ^a   Popovic, Daniela ^a   Hertrampf, Anke ^a   Kuntz, Sabine ^a   Boll, Michael ^a   Wenzel, Uwe ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Catenin; ABC transporters; Apoptosis; Caspases; Chrysin; Topotecan

Indexed keywords

ABC TRANSPORTER; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CASPASE; CHRYSIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; TOPOTECAN;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE G1 PHASE; CELL STRAIN CACO 2; CHROMATIN CONDENSATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOSOL; DNA FRAGMENTATION; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY;

APOPTOSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CELLS, CULTURED; DRUG ANTAGONISM; DRUG RESISTANCE, NEOPLASM; FLAVONOIDS; HUMANS; K562 CELLS; TOPOTECAN;

EID: 77953917443     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.038     Document Type: Article

References (47)

1. Dietrich C.G., Geier A., Oude Elferink R.P. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003, 52:1788-1795.
2. Chan L.M., Lowes S., Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004, 21:25-51.
3. Suzuki H., Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev 2002, 54:1311-1331.
4. Doyle L.A., Ross D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003, 22:7340-7358.
5. Matsson P., Pedersen J.M., Norinder U., Bergström C.A., Artursson P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 2009, 26:1816-1831.
6. Murakami T., Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol 2008, 4:923-939.
7. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38:802-832.
8. O'Connor R. The pharmacology of cancer resistance. Anticancer Res 2007, 27:1267-1272.
9. Su Y., Lee S.H., Sinko P.J. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. Eur J Pharm Sci 2006, 29:102-110.
10. Alvarez A.I., Real R., Pérez M., Mendoza G., Prieto J.G., Merino G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2009, 99:598-617.
11. Cao J., Chen X., Liang J., Yu X.Q., Xu A.L., Chan E., et al. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra. Drug Metab Dispos 2007, 35:539-553.
12. Pulido M.M., Molina A.J., Merino G., Mendoza G., Prieto J.G., Alvarez A.I. Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): Influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther 2006, 9:279-287.
13. Wang Y., Cao J., Zeng S. Involvement of Pglycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J Pharm Pharmacol 2005, 57:751-758.
14. Vaidyanathan J.B., Walle T. Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res 2001, 18:1420-1425.
15. Brand W., van der Wel P.A., Rein M.J., Barron D., Williamson G., van Bladeren P.J., et al. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 2008, 36:1794-1802.
16. Näthke I. Cytoskeleton out of the cupboard: colon cancer and cytoskeletal changes induced by loss of APC. Nat Rev Cancer 2006, 6:967-974.
17. van der Sandt I.C., Blom-Roosemalen M.C., de Boer A.G., Breimer D.D. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci 2000, 11:207-214.
18. Förster F., Volz A., Fricker G. Compound profiling for ABCC2 (MRP2) using a fluorescent microplate assay system. Eur J Pharm Biopharm 2008, 69:396-403.
19. Hooijberg J.H., Peters G.J., Kaspers G.J., Wielinga P.R., Veerman A.J., Pieters R., et al. Online fluorescent method to assess BCRP/ABCG2 activity in suspension cells. Nucleosides Nucleotides Nucleic Acids 2004, 23:1451-1454.
20. Li H., Jin H.E., Kim W., Han Y.H., Kim D.D., Chung S.J., et al. Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells. Pharm Res 2008, 25:2601-2612.
21. Gryczynski I., Gryczynski Z., Lakowicz J.R., Yang D., Burke T.G. Fluorescence spectral properties of the anticancer drug topotecan by steady-state and frequency domain fluorometry with one-photon and multi-photon excitation. Photochem Photobiol 1999, 69:421-428.
22. Boyarsky G., Hanssen C., Clyne L.A. Inadequacy of high K+/nigericin for calibrating BCECF. II. Intracellular pH dependence of the correction. Am J Physiol 1996, 271:C1146-C1156.
23. Schagger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100kDa. Anal Biochem 1987, 166:368-379.
24. Pajak B., Orzechowski A. Overview how adenocarcinoma cancer cells avoid immune- and chemotherapy-induced apoptosis. Adv Med Sci 2006, 51:39-45.
25. Begley J., Ribas A. Targeted therapies to improve tumor immunotherapy. Clin Cancer Res 2008, 14:4385-4391.
26. Moscow J.A., Cowan K.H. Multidrug resistance. J Natl Cancer Inst 1988, 80:14-20.
27. Stavrovskaya A.A., Stromskaya T.P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry 2008, 73:592-604.
28. Lee C.H. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol 2010, 596:325-340.
29. Lohner K., Schnäbele K., Daniel H., Oesterle D., Rechkemmer G., Göttlicher M., et al. Flavonoids alter P-gp expression in intestinal epithelial cells in vitro and in vivo. Mol Nutr Food Res 2007, 51:293-300.
30. Serra A., Macià A., Romero M.P., Valls J., Bladé C., Arola L., et al. Bioavailability of procyanidin dimers and trimers and matrix food effects in in vitro and in vivo models. Br J Nutr 2010, 103:944-952.
31. Sergent T., Garsou S., Schaut A., De Saeger S., Pussemier L., Van Peteghem C., et al. Differential modulation of ochratoxin A absorption across Caco-2 cells by dietary polyphenols, used at realistic intestinal concentrations. Toxicol Lett 2005, 159:60-70.
32. van der Flier L.G., Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol 2009, 71:241-260.
33. Wong J.M., de Souza R., Kendall C.W., Emam A., Jenkins D.J. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006, 40:235-243.
34. Tainton K.M., Smyth M.J., Jackson J.T., Tanner J.E., Cerruti L., Jane S.M., et al. Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 2004, 11:1028-1037.
35. Smyth M.J., Krasovskis E., Sutton V.R., Johnstone R.W. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci 1998, 95:7024-7029.
36. Matsuyama S., Llopis J., Deveraux Q.L., Tsien R.Y., Reed J.C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nature Cell Biol 2000, 2:318-325.
37. Robinson L.J., Roberts W.K., Ling T.T., Lamming D., Sternberg S.S., Roepe P.D. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997, 36:11169-11178.
38. Johnstone R.W., Ruefli A.A., Smyth M.J. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci 2000, 25:1-6.
39. Shitashige M., Hirohashi S., Yamada T. Wnt signaling inside the nucleus. Cancer Sci 2008, 99:631-637.
40. Gavert N., Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. J Cell Biochem 2007, 102:820-828.
41. Steinhusen U., Badock V., Bauer A., Behrens J., Wittman-Liebold B., Dörken B., et al. Apoptosis-induced cleavage of beta-catenin by caspase-3 results in proteolytic fragments with reduced transactivation potential. J Biol Chem 2000, 275:16345-16353.
42. Maier T.J., Janssen A., Schmidt R., Geisslinger G., Grösch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005, 19:1353-1355.
43. Lim J.C., Kania K.D., Wijesuriya H., Chawla S., Sethi J.K., Pulaski L., et al. Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 2008, 106:1855-1865.
44. Mariadason J.M., Bordonaro M., Aslam F., Shi L., Kuraguchi M., Velcich A., et al. Down-regulation of beta-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 2001, 61:3465-3471.
45. Kirkland S.C. Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. Br J Cancer 2009, 101:320-326.
46. Vincan E., Leet C.S., Reyes N.I., Dilley R.J., Thomas R.J., Phillips W.A. Sodium butyrate-induced differentiation of human LIM2537 colon cancer cells decreases GSK-3beta activity and increases levels of both membrane-bound and Apc/axin/GSK-3beta complex-associated pools of beta-catenin. Oncol Res 2000, 12:193-201.
47. Chaudhary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66:85-94.